HomeCompareWJXFF vs ABBV

WJXFF vs ABBV: Dividend Comparison 2026

WJXFF yields 4.35% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WJXFF wins by $67.1K in total portfolio value· pulled ahead in Year 6
10 years
WJXFF
WJXFF
● Live price
4.35%
Share price
$23.47
Annual div
$1.02
5Y div CAGR
40%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$169.5K
Annual income
$66,130.20
Full WJXFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WJXFF vs ABBV

📍 WJXFF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWJXFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WJXFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WJXFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WJXFF
Annual income on $10K today (after 15% tax)
$369.87/yr
After 10yr DRIP, annual income (after tax)
$56,210.67/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, WJXFF beats the other by $35,154.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WJXFF + ABBV for your $10,000?

WJXFF: 50%ABBV: 50%
100% ABBV50/50100% WJXFF
Portfolio after 10yr
$135.9K
Annual income
$45,450.98/yr
Blended yield
33.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WJXFF
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
3.1
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WJXFF buys
0
ABBV buys
0
No recent congressional trades found for WJXFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWJXFFABBV
Forward yield4.35%3.06%
Annual dividend / share$1.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40%40.6%
Portfolio after 10y$169.5K$102.3K
Annual income after 10y$66,130.20$24,771.77
Total dividends collected$137.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: WJXFF vs ABBV ($10,000, DRIP)

YearWJXFF PortfolioWJXFF Income/yrABBV PortfolioABBV Income/yrGap
1$11,309$609.20$11,550$430.00$241.00ABBV
2$13,002$901.44$13,472$627.96$470.00ABBV
3$15,268$1,356.03$15,906$926.08$638.00ABBV
4$18,421$2,083.47$19,071$1,382.55$650.00ABBV
5$22,999$3,288.85$23,302$2,095.81$303.00ABBV
6← crossover$29,982$5,372.68$29,150$3,237.93+$832.00WJXFF
7$41,244$9,163.91$37,536$5,121.41+$3.7KWJXFF
8$60,626$16,494.27$50,079$8,338.38+$10.5KWJXFF
9$96,592$31,722.70$69,753$14,065.80+$26.8KWJXFF
10$169,484$66,130.20$102,337$24,771.77+$67.1KWJXFF

WJXFF vs ABBV: Complete Analysis 2026

WJXFFStock

Wajax Corporation provides sales, parts, and services to construction, forestry, mining, industrial/commercial, oil sands, transportation, metal processing, government, utilities, and oil and gas sectors. The company offers compact excavators, dump trucks, excavators, wheel loaders, and wheeled excavators; aerial devices, boom lifts, cranes, digger derricks, drills, lifts, and material and scissor lifts; engines and transmissions; and feller bunchers, felling heads, flail debarkers, forestry processors, forwarders, grinders, log loaders, skidders, track and wheel harvesters, and wood chippers. It also provides bearings, bulk material handling, filtration, fluid handling, hydraulics, industrial electric motors and variable frequency drives, instrumentation, pneumatics, power transmissions, and safety and mill supplies, as well as sealing, belting, lubricants, and hydraulic hoses; combination sweeper scrubbers, container handlers, electric ride scooters, end rider trucks, forklifts, order pickers, pallet stackers and trucks, reach stackers, rider and walk behind sweepers, side loaders, tow tractors, and utility vehicles; and equipment transport, filtration, fluid handling, mining excavators, rigid frame trucks, rope shovel, underground battery powered and drill jumbos, underground haul trucks and loaders, underground roof bolters and scaling machines, and underground utility trucks. In addition, the company offers power generation solutions; and cages and partitions, guarding and barriers, lockers, cabinets, workstations, rack accessories and protections, racking, shelving, and storage platforms, as well as storage system design, installation, and inspection services. The company was formerly known as Wajax Income Fund and changed its name to Wajax Corporation in January 2011. Wajax Corporation was founded in 1858 and is headquartered in Mississauga, Canada.

Full WJXFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WJXFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WJXFF vs SCHDWJXFF vs JEPIWJXFF vs OWJXFF vs KOWJXFF vs MAINWJXFF vs JNJWJXFF vs MRKWJXFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.